JP2023521887A - コロナウイルス治療のためのピルフェニドン - Google Patents

コロナウイルス治療のためのピルフェニドン Download PDF

Info

Publication number
JP2023521887A
JP2023521887A JP2022562668A JP2022562668A JP2023521887A JP 2023521887 A JP2023521887 A JP 2023521887A JP 2022562668 A JP2022562668 A JP 2022562668A JP 2022562668 A JP2022562668 A JP 2022562668A JP 2023521887 A JP2023521887 A JP 2023521887A
Authority
JP
Japan
Prior art keywords
pirfenidone
sustained release
cov
subject
sars
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022562668A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023521887A5 (enExample
Inventor
アギラー－コルドバ，エストゥアルド
アギラー，ローラ
カストロ，ホセ アグスティン ロゲリオ マガニャ
Original Assignee
エクスカリバー ファーマシューティカルズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エクスカリバー ファーマシューティカルズ，インク． filed Critical エクスカリバー ファーマシューティカルズ，インク．
Publication of JP2023521887A publication Critical patent/JP2023521887A/ja
Publication of JP2023521887A5 publication Critical patent/JP2023521887A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
JP2022562668A 2020-04-14 2021-04-14 コロナウイルス治療のためのピルフェニドン Pending JP2023521887A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063010009P 2020-04-14 2020-04-14
US63/010,009 2020-04-14
PCT/US2021/027335 WO2021211745A1 (en) 2020-04-14 2021-04-14 Pirfenidone for coronavirus treatment

Publications (2)

Publication Number Publication Date
JP2023521887A true JP2023521887A (ja) 2023-05-25
JP2023521887A5 JP2023521887A5 (enExample) 2024-04-25

Family

ID=78084909

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022562668A Pending JP2023521887A (ja) 2020-04-14 2021-04-14 コロナウイルス治療のためのピルフェニドン

Country Status (14)

Country Link
US (1) US20230117397A1 (enExample)
EP (1) EP4135671A4 (enExample)
JP (1) JP2023521887A (enExample)
KR (1) KR20230038644A (enExample)
CN (1) CN115916162A (enExample)
AU (1) AU2021254765A1 (enExample)
BR (1) BR112022020821A2 (enExample)
CA (1) CA3175526A1 (enExample)
CL (1) CL2022002843A1 (enExample)
CO (1) CO2022016155A2 (enExample)
EC (1) ECSP22087664A (enExample)
IL (1) IL297296A (enExample)
MX (1) MX2022012986A (enExample)
WO (1) WO2021211745A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
CN114796122B (zh) * 2022-03-30 2023-03-24 山东大学 一种聚多巴胺载吡菲尼酮纳米粒及其制备方法和应用
JP7845721B2 (ja) * 2022-04-29 2026-04-14 オーバーシーズ ファーマシューティカルズ リミテッド ピルフェニドンの経口用持続放出性固形製剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009509962A (ja) * 2005-09-22 2009-03-12 インターミューン インコーポレイテッド ピルフェニドンおよび薬学的に受容可能な賦形剤のカプセル処方物
JP2014522861A (ja) * 2011-07-19 2014-09-08 セル セラピー アンド テクノロジー，エス．エー． デーイー シー．ヴィ． 徐放錠の形態でピルフェニドンを含有する医薬組成物の調製のためのプロセスならびにヒトの慢性腎不全、乳房被膜拘縮および肝線維症の退行におけるその適用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU709178B2 (en) * 1995-09-19 1999-08-26 Intermune, Inc. Inhibition of tumor necrosis factor alpha
US20020028784A1 (en) * 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
WO2003030720A2 (en) * 2001-10-09 2003-04-17 The Children's Hospital Of Philadelphia Materials and methods for preventing or reducing scar formation
US20070072181A1 (en) * 2003-02-28 2007-03-29 Blatt Lawrence M Combination therapy for treating alphavirus infection and liver fibrosis
US20080025986A1 (en) * 2003-06-06 2008-01-31 Ozes Osman N Methods of Treating Tnf-Mediated Disorders
US7407973B2 (en) * 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
MX2007014114A (es) * 2005-05-10 2008-03-14 Intermune Inc Derivados de piridona para modular el sistema de proteina cinasa activada por estres.
CN101088557A (zh) * 2006-06-12 2007-12-19 天津市扶素生物技术有限公司 用于预防或治疗hiv感染的药用组合物及其应用
US20080287508A1 (en) * 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
SG176053A1 (en) * 2009-05-15 2011-12-29 Intermune Inc Methods of treating hiv patients with anti-fibrotics
CN101972236A (zh) * 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 一种含吡非尼酮的缓释制剂
ES2913095T3 (es) * 2011-01-31 2022-05-31 Avalyn Pharma Inc Compuestos de pirfenidona y análogos de piridona en aerosol y usos de los mismos
WO2013181691A1 (en) * 2012-06-04 2013-12-12 The Macfarlane Burnet Institute For Medical Research And Public Health Ltd A method of treatment and compositions useful therefor, screening and prognostic agents and uses therefor
EP4491180A1 (en) * 2014-01-10 2025-01-15 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009509962A (ja) * 2005-09-22 2009-03-12 インターミューン インコーポレイテッド ピルフェニドンおよび薬学的に受容可能な賦形剤のカプセル処方物
JP2014522861A (ja) * 2011-07-19 2014-09-08 セル セラピー アンド テクノロジー，エス．エー． デーイー シー．ヴィ． 徐放錠の形態でピルフェニドンを含有する医薬組成物の調製のためのプロセスならびにヒトの慢性腎不全、乳房被膜拘縮および肝線維症の退行におけるその適用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HUI DAI ET AL.: ""High-resolution Chest CT Features and Clinical Characteristics of Patients Infected with COVID-19", INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, vol. 95, JPN7025002334, 6 April 2020 (2020-04-06), pages 106 - 112, ISSN: 0005737813 *
HUILAN ZHANG: "A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infec", CLINICALTRIALS.GOV, JPN7025002333, 21 February 2020 (2020-02-21), pages 04282902, ISSN: 0005737812 *
Z．F. XU ET AL.: ""Key Points of Clinical and CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV) Imported Pneu", UNDEFINED, JPN6025021726, 6 March 2020 (2020-03-06), ISSN: 0005737814 *

Also Published As

Publication number Publication date
CA3175526A1 (en) 2021-10-21
US20230117397A1 (en) 2023-04-20
EP4135671A1 (en) 2023-02-22
IL297296A (en) 2022-12-01
EP4135671A4 (en) 2024-08-14
WO2021211745A1 (en) 2021-10-21
BR112022020821A2 (pt) 2022-12-20
CL2022002843A1 (es) 2023-09-01
MX2022012986A (es) 2023-03-21
ECSP22087664A (es) 2022-12-30
AU2021254765A1 (en) 2022-12-08
KR20230038644A (ko) 2023-03-21
CO2022016155A2 (es) 2022-12-20
CN115916162A (zh) 2023-04-04

Similar Documents

Publication Publication Date Title
US20230117397A1 (en) Pirfenidone for coronavirus treatment
JP5781606B2 (ja) インフルエンザ、一般的な感冒および炎症の治療におけるレボセチリジンおよびモンテルカストの使用
JP2007291067A (ja) 医薬組成物
CN113633649A (zh) 瑞德西韦及其核苷的组合制剂在抗猪流行性腹泻病毒中的应用
JP2010083871A (ja) 抗アデノウイルス剤を含有する医薬組成物
JP5232520B2 (ja) ロキソプロフェンを含有する抗アデノウイルス剤
JP4829478B2 (ja) 医薬組成物
WO2024051793A1 (en) METHODS ANS KITS FOR TREATING SARS-CoV-2 INFECTION
JP4444721B2 (ja) 医薬組成物
US7199153B2 (en) Pharmaceutical composition comprising paracetamol and niflumic acid
JP2004331660A (ja) 医薬組成物
CN116036084A (zh) 千金藤素在制备治疗冠状病毒感染患者的药物中的用途
US20230310467A1 (en) PHARMACEUTICAL COMBINATION THERAPY AND PREVENTION WITH APROTININ + REMDESIVIR OF SARS-CoV-2 AND/OR DISEASE ASSOCIATED WITH THIS INFECTION, INCLUDI COVID-19
JP5128532B2 (ja) 医薬組成物
TW202143985A (zh) 治療之方法
WO2025171802A1 (zh) 雷贝拉唑药物组合物、其制备方法及应用
HK1199815B (en) Levocetirizine and montelukast for the treatment of influenza and common cold
JP2008285474A (ja) 抗アデノウイルス剤を含有する医薬組成物
Olney Relenza: generic name: zanamivir
JP2009143966A (ja) 医薬組成物
JP2010106012A (ja) 抗アデノウイルス剤及びそれを含有する医薬組成物
CN102552257A (zh) 一种含有盐酸雷尼替丁和曲昔派特的复方制剂及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240415

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250529

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251125